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The lung is a very common site for metastatic disease.
It is clinically important to differentiate between pri-
mary and secondary lung adenocarcinomas, because
treatment and prognosis differ for patients with these
malignancies. Pathologists are often asked to identify
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The objectives of this study were firstly to compare the immunostaining patterns of antibodies
against caveolin-1, thyroid transcription factor-1 (TTF-1), cytokeratin 7 (CK7) and cytokeratin 20
(CK20) in primary and secondary pulmonary adenocarcinomas of breast or colonic origin, and
secondly, to investigate their use alone and in combination, in distinguishing between primary
and secondary lung adenocarcinomas from breast or colonic origin. Of the 49 lung adenocarcinoma
specimens that were enrolled in this study, 30 were primary pulmonary adenocarcinomas, and 
19 (9, breast origin; 10, colonic origin) were metastatic pulmonary carcinomas. Immunohistochemical
staining was used to detect the expression of caveolin-1, TTF-1, CK7, and CK20. Primary pul-
monary adenocarcinoma most often had the CK7-positive/CK20-negative immunohistochemi-
cal phenotype and was either TTF-1 positive or caveolin-1 negative. Secondary pulmonary
adenocarcinoma of breast origin most often had the CK7-positive/CK20-negative immunohisto-
chemical phenotype and was either TTF-1 negative or caveolin-1 positive, while secondary pul-
monary adenocarcinoma of colonic origin most often had the CK20-positive/CK7-negative
immunohistochemical phenotype and was either TTF-1 negative or caveolin-1 positive. The results
suggest that caveolin-1, TTF-1, or CK7/CK20 alone did not distinguish reliably between primary
and secondary pulmonary adenocarcinomas originating from breast or colon. The use of a panel
of antibodies that includes TTF-1, caveolin-1, and CK7/CK20 may have higher sensitivity in dis-
criminating between primary adenocarcinomas and metastatic lung adenocarcinomas from breast
or colonic origin.
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the primary site. It has been reported that immuno-
histochemistry is a useful method for ascertaining the
site of origin in such cases. However, until recently,
the use of immunohistochemistry was hampered by
the lack of commercially available antibodies that are
specific for lung tumor-associated antigens.
Caveolin-1, a metastasis-promoting molecule, was
first discovered as a tyrosine-phosphorylated target
in Rous sarcoma virus (RSV)-transformed avian fibro-
blasts, suggesting a possible role for this protein in
cellular transformation [1,2]. It is also the principal
component of caveolae, which has been recognized
as a key player in the regulation of several signal trans-
duction molecules [3–5]. Recently, elevated expres-
sion of caveolin-1 was found to be associated with
metastases and poor prognosis of prostate, esophageal
and pancreatic carcinomas [6–8].
Thyroid transcription factor-1 (TTF-1), a 38-kDa
protein, is located primarily in the nuclei of type II
pneumocytes and Clara’s cells in the lung, thyroid
tissues, and the diencephalons of the brain [9,10].
Markers have recently been described to recognize
carcinomas of pulmonary or thyroid origin. In lung
cancer a high frequency of TTF-1 expression has been
observed in small cell carcinomas (85–90%) and in
adenocarcinoma (75–80%) [11].
Cytokeratin 7 (CK7), a 54-kDa basic cytokeratin
protein, is expressed in a wide variety of epithelia, such
as lung, breast, endometrium, urothelium, stomach,
and skin adnexal glands [12]. Cytokeratin 20 (CK20)
is a 46-kDa acidic protein and is distributed predomi-
nantly in carcinomas of the gastrointestinal, pancre-
atobiliary tracts, and mucinous ovarian tumors [13].
The coordinated expression of CK7 and CK20 has
been used to determine the site of origin of carcino-
mas [14,15]. Each immunophenotype is associated
with a group of epithelial neoplasms. For example,
the CK7-positive/CK20-negative phenotype is seen
in a wide variety of carcinomas, including those of
the lung, breast and female genital tract, whereas the
CK7-negative/CK20-positive phenotype is often asso-
ciated with carcinomas of colorectal origin [15].
Limited information is available in the literature
regarding the comparison of the diagnostic utility 
of these markers in distinguishing between primary
lung carcinomas and nonpulmonary neoplasms. In
the present study, we compared the immunostaining
patterns of antibodies against caveolin-1, TTF-1, CK7,
and CK20 in primary and secondary pulmonary 
adenocarcinomas, in addition to investigating their use
alone and in combination for distinguishing between
primary and secondary lung carcinomas from the
breast or colon.
MATERIALS AND METHODS
Tissue specimens were obtained from 49 cases of lung
adenocarcinoma diagnosed at the Department of
Pathology, Kaohsiung Medical University Chung-Ho
Memorial Hospital, between 1998 and 2004. All tumors
were surgical resection specimens. There were 30 pri-
mary pulmonary adenocarcinomas, nine metastatic
adenocarcinomas from the breast, and 10 metastatic
adenocarcinomas from the colon.
Hematoxylin and eosin staining was performed
and the slides were examined under light micro-
scope. Tissue microarray was prepared according to
the authors’ published method [16]. For each donor
tissue block, two tissue cores were punched with a
bone marrow aspiration needle (2 mm diameter). The
cylinder was carefully transferred with forceps to a
recipient metal paraffin block box. After all the cylin-
ders were aligned in the box, the box was covered
with a plastic cassette and then liquid wax was 
gently poured into the box until full. The box was
then cooled to room temperature slowly. Before sec-
tioning, the tissue array paraffin blocks were chilled
to −20°C and removed from the box. Three-micrometer
sections were cut and mounted on silane-coated
slides. 
For immunostaining, deparaffinized and rehy-
drated sections were heated in an oven at 121°C for
30 minutes in citrate buffer to retrieve antigenic activ-
ity and then they were cooled at room temperature.
Endogenous peroxidase activity was inhibited by
incubation with 0.3% hydrogen peroxide in methanol
for 20 minutes. After nonspecific reactions had been
blocked with 10% normal bovine serum, the sections
were incubated with polyclonal antibodies to caveolin-
1 alpha-isoform (1:50; Chemicon, USA) for 3 hours,
and monoclonal antibodies to TTF-1 (1:50; M3575;
DAKO), to CK7 (1:50; M7018; DAKO), and to CK20
(1:50; M7019; DAKO) for 40 minutes. The sections were
first incubated with biotinylated goat anti-mouse/
rabbit immunoglobulin (Ig) for 20 minutes and then
with streptavidin–peroxidase complex for 20 minutes.
Careful rinses were performed with several changes
of phosphate-buffered saline between each stage of
the procedure. Finally, the sections were incubated in
3,3′-diaminobenzidine for 5 minutes. The slides were
then rinsed gently with distilled water, counterstained
in hematoxylin, dehydrated and mounted. Negative
controls were performed by replacing the primary
antibody with nonimmune rabbit IgG.
The staining slides were evaluated by two pathol-
ogists (Wang and Chai) who were blinded to knowl-
edge of the clinicopathologic data. The intensity of the
caveolin-1 immunostaining was evaluated by light
microscopy as described elsewhere [17]. Caveolin-1
intensity was graded as follows: 1, no staining; 2, weak
staining; 3, moderate staining; and 4, strong staining.
For the purpose of further analysis, using a cut-off
point to define two groups of negative and positive
caveolin-1 expression, grades 1 or 2 were regarded as
negative, and grades 3 or 4 were regarded as positive
(Figure A). TTF-1 expression was based on the presence
of nuclear staining whereas CK7 and CK20 expressions
were based on the presence of cytoplasmic staining.
Tumors were considered to show negative immuno-
staining if staining was found in fewer than 10% of
neoplastic cells and positive if staining was present in
more than 10% (Figure B–D).
RESULTS
Patient ages ranged from 28 to 78 years (mean, 46.7
years) and the male-to-female ratio was 0.75 (21 males;
28 females).
The immunohistochemical findings are summa-
rized in Table 1. TTF-1 and caveolin-1 positivity was
shown in 70% (21/30) and 27% (8/30) of primary
pulmonary adenocarcinomas. The CK7-positive/
CK20-negative and CK7-negative/CK20-positive
immunostaining patterns were demonstrated in 77%
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Figure. (A) Breast origin lung adenocarcinoma shows strong staining for caveolin-1. (B) Primary lung adenocarcinoma shows strong
staining for thyroid transcription factor-1. (C) Breast origin lung adenocarcinoma shows strong staining for cytokeratin 7. (D) Colonic
origin lung adenocarcinoma shows strong staining for cytokeratin 20 (original magnification, 200×).
(23/30) and 23% (7/30) of primary pulmonary ade-
nocarcinomas. TTF-1 was not shown in metastatic pul-
monary adenocarcinomas while caveolin-1 positivity
was evident in 78% (7/9) and 60% (6/10) of metastatic
pulmonary adenocarcinomas. A CK7-positive/CK20-
negative immunostaining pattern was demonstrated
in 56% (5/9) of pulmonary adenocarcinomas of breast
origin, while a CK7-negative/CK20-positive immuno-
staining pattern was demonstrated in 90% (9/10) 
of pulmonary adenocarcinomas of colonic origin.
Forty-four percent (4/9) of pulmonary adenocarcino-
mas of breast origin and 10% (1/9) of colonic origin
showed a CK7-negative/CK20-negative immunostain-
ing pattern.
Of the 23 CK7-positive/CK20-negative primary
lung adenocarcinomas, only 30% (7/23) were caveolin-
1 positive. Caveolin-1 was expressed in 100% (5/5) of
CK7-positive/CK20-negative pulmonary adenocar-
cinomas of breast origin (Table 2). Caveolin-1 positiv-
ity was demonstrated in 56% (5/9) of CK7-negative/
CK20-positive metastatic pulmonary adenocarcinomas
of colonic origin (Table 3).
According to the above findings, the primary 
pulmonary adenocarcinoma most often has the CK7-
positive/CK20-negative immunohistochemical phe-
notype and can be either TTF-1 positive or caveolin-1
negative. The secondary pulmonary adenocarcinoma
of breast origin most often has the CK7-positive/
CK20-negative immunohistochemical phenotype
and can be either TTF-1 negative or caveolin-1 posi-
tive. The secondary pulmonary adenocarcinoma of
colonic origin most often has the CK20-positive/
CK7-negative immunohistochemical phenotype and
can be either TTF-1 negative or caveolin-1 positive.
DISCUSSION
It is important to determine whether a lung tumor 
is primary or secondary lung adenocarcinoma,
because the treatment protocol and prognosis differ
considerably for patients with these malignancies. 
A reliable immunohistochemical marker is required
in differentiation between these malignancies. In this
study, we compared four antibodies—caveolin-1,
TTF-1, CK7 and CK20—as markers of primary and
secondary lung adenocarcinomas of breast or colonic
origin.
Caveolin-1 plays a key role in membrane traffic,
normal vesicular transport, cholesterol homeostasis,
and signal transduction [18]. Animal studies have
found that caveolin-1 is most abundant in adipocytes,
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Table 1. Results of immunohistochemical staining of primary and secondary pulmonary adenocarcinomas for caveolin-1,
thyroid transcription factor-1 (TTF-1), cytokeratin 7 (CK7), and cytokeratin 20 (CK20)
Immunomarker Lung origin (n = 30) Breast origin (n = 9) Colonic origin (n = 10)
TTF-1
Positive 21 (70%) 0 (0%) 0 (0%)
Caveolin-1
Positive 8 (27%) 7 (78%) 6 (60%)
CK7/CK20
CK7-positive/CK20-positive 0 (0%) 0 (0%) 0 (0%)
CK7-positive/CK20-negative 23 (77%) 5 (56%) 0 (0%)
CK7-negative/CK20-positive 7 (23%) 0 (0%) 9 (90%)
CK7-negative/CK20-negative 0 (0%) 4 (44%) 1 (10%)
Table 2. Caveolin-1 expression in cytokeratin 7 (CK7)-
positive/cytokeratin 20 (CK20)-negative primary and
metastatic pulmonary adenocarcinomas of breast origin
Lung origin (n = 23) Breast origin (n = 5)
Caveolin-1
Positive 7 (30%) 5 (100%)
Negative 16 (70%) 0 (0%)
Table 3. Caveolin-1 expression in cytokeratin 7 (CK7)-
negative/cytokeratin 20 (CK20)-positive metastatic pul-
monary adenocarcinoma of colonic origin




endothelial cells, type I pneumocytes, fibroblasts and
smooth muscle cells [18]. The application of caveolin-1
immunoexpression in predicting prognosis has been
reported in some malignancies, such as squamous
cell carcinoma of lung, pleomorphic carcinoma of lung,
and clear-cell renal cell carcinoma [17,19,20]. Other
studies have reported that caveolin-1 expression was
upregulated in human cancers, including esophageal
squamous cell carcinoma, lung adenocarcinoma and
prostate cancer, and also that this upregulation was
associated with metastasis [6,7,21]. The present study
similarly reported that the intensity of caveolin-1
increased in secondary adenocarcinoma, be it either
of breast or colonic origin. This research indicated
that caveolin-1 plays a role in cancer cell metastasis.
Several previous studies have found that TTF-1 was
useful as a marker of pulmonary carcinoma in histo-
logic specimens [11,22–24]. Immunoreactivity for TTF-1
was present in 70–90% of primary pulmonary carci-
nomas. All metastatic breast or gastrointestinal ade-
nocarcinomas were nonreactive for TTF-1. Similar
results were obtained in our study. Although TTF-1
was fairly specific for pulmonary carcinomas, it
showed a lower sensitivity for pulmonary carcinoma
and, thus, was not useful as an independent marker
in differentiating between primary pulmonary ade-
nocarcinoma and metastatic adenocarcinoma.
Since the early 1990s, the clinical utility of mono-
clonal antibodies directed against CK20 paired with
anti-CK7 antibodies in the differential diagnosis of
primary and secondary lung cancers has been reported
[25]. Adenocarcinoma from the colon is usually CK7
positive/CK20 negative, whereas adenocarcinoma
from the lung or breast is usually CK7 negative/CK20
positive [26]. Although our present study obtained the
same result, the combined panel of CK7/CK20 cer-
tainly has relatively low sensitivity and low specificity.
There is no report on the use of an antibody panel
combining CK7, CK20, TTF-1, and caveolin-1 in dif-
ferentiating between primary and secondary pul-
monary adenocarcinomas of breast or colonic origin.
In the current study, we confirmed that CK7, CK20,
and TTF-1 expression are useful as immunohistochem-
ical markers for the diagnosis of lung tumors and 
for the differential diagnosis of primary pulmonary
adenocarcinomas from extrapulmonary adenocar-
cinomas metastatic to the lung. On the other hand,
the accuracy of diagnosis seemed to increase when
caveolin-1 was added to the panel of TTF-1 combined
with CK7/CK20. In conclusion, we suggest that a
panel comprising caveolin-1, TTF-1 and CK7/CK20
immunostains would be beneficial in the differential
diagnosis of primary and secondary lung cancers of
breast or colonic origin.
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